Arbutus Pharma
ABUS4.3152.15% ( -0.095 )
Arbutus Pharma (ABUS)
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic...
- Open
- 4.410
- High
- 4.430
- Low
- 4.270
- Prev. Close
- 4.410
- Volume
- 1.45M
- Turnover
- 6.27M
- Avg Price
- 4.314
- Bid/Ask Ratio
- --
- Amplitude
- 3.63%
- 52wk High
- 5.380
- Volume Ratio
- 1.26
- Turnover Ratio
- 1.15%
Arbutus Pharma Analyst Rating
View MoreForecast & Rating
Jul 16, 2026Price forecast
$5.1820.11%
Forecast & RatingStrong buy
2analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · Jul 16 at 08:08 AM
Arbutus Biopharma shares are trading higher after the company announced the filing of three international lawsuits seeking to enforce patent protecting LNP technology against Pfizer, BioNTech and certain or other affiliates.
- TradingView · Jul 16 at 06:33 AM
Arbutus Biopharma Ends RSV Agreement With Genevant; Receives $1 Million Termination Fee
- PUBT · Jul 16 at 06:32 AM
Arbutus files patent infringement suits against Pfizer, BioNTech over LNP technology
- TradingView · May 14 at 02:54 AM
Key facts: ABUS Q1 $179.1M revenue; $169.7M net, $0.05 adj loss
- Earnings Watch · May 13 at 06:33 AM
Arbutus Pharma | 10-Q: FY2026 Q1 Revenue: USD 179.13 M
- Earnings Watch · May 13 at 06:33 AM
Arbutus Pharma | 8-K: FY2026 Q1 Revenue: USD 179.13 M
